Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | PIK3R2 | O00459 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5518979 | 0.85 | ACHE (0.40) | BCHEACHEELANECTRB1PIK3CD | |
| SCHEMBL5512094 | 0.85 | ACHE (0.56) | BCHEACHE | |
| SCHEMBL5511760 | 0.82 | ELANE (0.39) | BCHEACHEELANECTRB1PIK3CD | |
| SCHEMBL5510773 | 0.81 | TUBB4A (0.43) | BCHEACHE | |
| SCHEMBL5509751 | 0.80 | ACHE (0.44) | BCHEACHE | |
| SCHEMBL5506248 | 0.78 | ACHE (0.51) | BCHEACHE | |
| SCHEMBL5506377 | 0.77 | ACHE (0.42) | BCHEACHE | |
| SCHEMBL5511094 | 0.77 | GAA (0.43) | BCHEACHEPIK3CDPIK3CG | |
| SCHEMBL5508714 | 0.76 | ACHE (0.44) | BCHEACHE | |
| SCHEMBL6427046 | 0.76 | GAA (0.34) | BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521583-B1 | 7,8,9,10-TETRAHYDRO-6H-AZEPINO, 6,7,8,9-TETRAHYDRO-PYRIDO AND 2,3-DIHYDRO-2H-PYRROLO (2,1-B)-QUINAZOLINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-01-10 | — | — | EP | disclosed |
| US-7067519-B2 | 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-06-27 | — | — | US | disclosed |
| US-20050009852-A1 | 7 8 9 10-tetrahydro-6h-azepino, 6 7 8 9-tetrahydro-pyrido and 2 3-dihydro-2h-pyrrolo[2 1-b]-quinazolinone derivates | ACTELION PHARMACEUTICALS, LTD. (CH) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009852-A1 | 7 8 9 10-tetrahydro-6h-azepino, 6 7 8 9-tetrahydro-pyrido and 2 3-dihydro-2h-pyrrolo[2 1-b]-quinazolinone derivates | HCRTR2, HCRTR1, NPY1R | BCHE 2964/4885ACHE 2967/4885ELANE 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.